Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar:: preliminary study

被引：7

作者：

Ndour, CT ^{[1
]}

Batista, G ^{[1
]}

Manga, NM ^{[1
]}

Guèye, NFN ^{[1
]}

Badiane, NMD ^{[1
]}

Fortez, L ^{[1
]}

Sow, PS ^{[1
]}

机构：

[1] CHU Fann, Clin Malad Infect Ibrahima Diop Mar, Dakar, Senegal

来源：

MEDECINE ET MALADIES INFECTIEUSES | 2006年 / 36卷 / 02期

关键词：

HIV-2; Senegal; HAART;

D O I：

10.1016/j.medmal.2005.11.012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objective. - The authors had for aim to evaluate the clinical and immunological response as well as the tolerance to antiretroviral therapy in HIV-2 infected patients. Design. - A retrospective chart review was made from August 1998 to August 2004. Results. - 188 patients were on protease inhibitor based regimen. 153 (81.38%) were HIV-1 and 35 (18.62%) HIV-2 infected patients. The mean weight gain was significantly higher in the HIV-2 group at months 9 and 12 (P = 0.02 et P = 0.01 respectively), whereas CD4 cells count gain was higher in the HIV-1 group at month 6 (P = 0.004). New AIDS defining criteria are less likely to occur in HIV-2 infected patients on HAART than in HIV-1 (P = 0.004). Lipodystrophy syndrome was present only in HIV-1 infected patients. Conclusion. - Antiretroviral therapy in HIV-2 infected patients shows similar clinical and immunological efficacy than in HIV-1 infected ones and is also well tolerated. (c) 2006 Elsevier SAS. Tous droits reserves.

引用

页码：111 / 114

页数：4

共 10 条

[1] Antiretroviral therapy in HIV-2-infected patients:: changes in plasma viral load, CD4+cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire [J].

Adjé-Touré, CA ;

Cheingsong, R ;

Garcìa-Lerma, JG ;

Eholié, S ;

Borget, MY ;

Bouchez, JM ;

Otten, RA ;

Maurice, C ;

Sassan-Morokro, M ;

Ekpini, RE ;

Nolan, M ;

Chorba, T ;

Heneine, W ;

Nkengasong, JN .

AIDS, 2003, 17 :S49-S54

[2] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].

Carr, A ;

Samaras, K ;

Chisholm, DJ ;

Cooper, DA .

LANCET, 1998, 351 (9119) :1881-1883

[3] Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor [J].

Fung, HB ;

Kirschenbaum, HL ;

Hameed, R .

CLINICAL THERAPEUTICS, 2000, 22 (05) :549-572

[4] The Senegalese government's highly active antiretroviral therapy initiative:: an 18-month follow-up study [J].

Laurent, C ;

Diakhaté, N ;

Gueye, NFN ;

Touré, MA ;

Sow, PS ;

Faye, MA ;

Gueye, M ;

Lanièce, I ;

Kane, CT ;

Liégeois, F ;

Vergne, L ;

Mboup, S ;

Badiane, S ;

Ndoye, I ;

Delaporte, E .

AIDS, 2002, 16 (10) :1363-1370

[5]

MALLAL AS, 2000, AIDS, V14, P33

[6] REDUCED RATE OF DISEASE DEVELOPMENT AFTER HIV-2 INFECTION AS COMPARED TO HIV-1 [J].

MARLINK, R ;

KANKI, P ;

THIOR, I ;

TRAVERS, K ;

EISEN, G ;

SIBY, T ;

TRAORE, I ;

HSIEH, CC ;

DIA, MC ;

GUEYE, E ;

HELLINGER, J ;

GUEYENDIAYE, A ;

SANKALE, JL ;

NDOYE, I ;

MBOUP, S ;

ESSEX, M .

SCIENCE, 1994, 265 (5178) :1587-1590

[7]

RUBINEK T, 1994, FEBBS LETT, V330, P299

[8] CELLULAR AND PLASMA VIRAL LOAD IN PATIENTS INFECTED WITH HIV-2 [J].

SIMON, F ;

MATHERON, S ;

TAMALET, C ;

LOUSSERTAJAKA, I ;

BARTCZAK, S ;

PEPIN, JM ;

DHIVER, C ;

GAMBA, E ;

ELBIM, C ;

GASTAUT, JA ;

SAIMOT, AG ;

BRUNVEZINET, F .

AIDS, 1993, 7 (11) :1411-1417

[9] Antiretroviral therapy for HIV-2 infected patients [J].

Smith, NA ;

Shaw, T ;

Berry, N ;

Vella, C ;

Okorafor, L ;

Taylor, D ;

Ainsworth, J ;

Choudhury, A ;

Daniels, RS ;

El-Gadi, S ;

Fakoya, A ;

Moyle, G ;

Oxford, J ;

Tedder, R ;

O'Shea, S ;

de Ruiter, A ;

Breuer, J .

JOURNAL OF INFECTION, 2001, 42 (02) :126-133

[10] Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients [J].

van der Ende, ME ;

Prins, AM ;

Brinkman, K ;

Keuter, M ;

Veenstra, A ;

Danner, SA ;

Niesters, HGM ;

Osterhaus, ADME ;

Schutten, M .

AIDS, 2003, 17 :S55-S61

← 1 →